Cargando…
Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
Patients enrolled in randomised clinical trials may not be representative of the real-world population of people with heart failure (HF). Older patients are frequently excluded and this limits the strength of evidence which supports the use of specific HF treatments in this patient group. Lack of ev...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545993/ https://www.ncbi.nlm.nih.gov/pubmed/31179014 http://dx.doi.org/10.15420/cfr.2019.6.2 |
_version_ | 1783423480812797952 |
---|---|
author | Stolfo, Davide Savarese, Gianluigi |
author_facet | Stolfo, Davide Savarese, Gianluigi |
author_sort | Stolfo, Davide |
collection | PubMed |
description | Patients enrolled in randomised clinical trials may not be representative of the real-world population of people with heart failure (HF). Older patients are frequently excluded and this limits the strength of evidence which supports the use of specific HF treatments in this patient group. Lack of evidence together with fear of adverse effects, drug interactions and lower tolerance may lead to the undertreatment of older patients and a less favourable outcome. Renin–angiotensin–aldosterone system (RAAS) inhibitors are the cornerstone of treatment for patients with HF with reduced ejection fraction (HFrEF), but despite the class I recommendation for all patients regardless of age in the guidelines, there are signs that RAAS inhibitors are underused among older patients. Large registry-based studies suggest that RAAS inhibitors may be at least as effective in older patients as younger ones, but these findings need to be confirmed by randomised clinical trials. |
format | Online Article Text |
id | pubmed-6545993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Radcliffe Cardiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-65459932019-06-07 Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction Stolfo, Davide Savarese, Gianluigi Card Fail Rev Clinical Practice Patients enrolled in randomised clinical trials may not be representative of the real-world population of people with heart failure (HF). Older patients are frequently excluded and this limits the strength of evidence which supports the use of specific HF treatments in this patient group. Lack of evidence together with fear of adverse effects, drug interactions and lower tolerance may lead to the undertreatment of older patients and a less favourable outcome. Renin–angiotensin–aldosterone system (RAAS) inhibitors are the cornerstone of treatment for patients with HF with reduced ejection fraction (HFrEF), but despite the class I recommendation for all patients regardless of age in the guidelines, there are signs that RAAS inhibitors are underused among older patients. Large registry-based studies suggest that RAAS inhibitors may be at least as effective in older patients as younger ones, but these findings need to be confirmed by randomised clinical trials. Radcliffe Cardiology 2019-05-24 /pmc/articles/PMC6545993/ /pubmed/31179014 http://dx.doi.org/10.15420/cfr.2019.6.2 Text en Copyright © 2019, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/legalcode This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly. |
spellingShingle | Clinical Practice Stolfo, Davide Savarese, Gianluigi Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction |
title | Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction |
title_full | Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction |
title_fullStr | Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction |
title_full_unstemmed | Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction |
title_short | Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction |
title_sort | use of renin–angiotensin–aldosterone system inhibitors in older patients with heart failure and reduced ejection fraction |
topic | Clinical Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545993/ https://www.ncbi.nlm.nih.gov/pubmed/31179014 http://dx.doi.org/10.15420/cfr.2019.6.2 |
work_keys_str_mv | AT stolfodavide useofreninangiotensinaldosteronesysteminhibitorsinolderpatientswithheartfailureandreducedejectionfraction AT savaresegianluigi useofreninangiotensinaldosteronesysteminhibitorsinolderpatientswithheartfailureandreducedejectionfraction |